Tim West

Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition

Petrice M Cogswell, Emily S. Lundt, Terry M. Therneau, Mingzhao Hu et autres

Associations of Alzheimer's disease biomarker progression with cognitive decline are important to inform patient prognosis. Of particular interest is how newly available plasma biomarkers evolve relative to cognitive decline. The goals of this work are to measure how much earlier versus later …

us (code pays fourni par la source)

Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia

Jihwan Yun, Jung‐Ah Lee, Daeun Shin, Eun Hye Lee et autres

Importance: Plasma phosphorylated p-tau 217 levels vary with biological factors such as kidney dysfunction, body mass index (BMI), and anemia. It remains unclear whether a biological subgroup-specific optimal cutoff or a double-cutoff strategy could enhance diagnostic accuracy and cost efficiency beyond the …

kr, se, gb, cn, fr, no, us (code pays fourni par la source)

Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment

Han‐Kyeol Kim, Jae Hoon Lee, Joong‐Hyun Chun, You Jin Kim et autres

INTRODUCTION: While positron emission tomography (PET) is the standard for pathological staging, its limited availability necessitates accessible alternatives. We evaluated plasma biomarkers for detecting PET-based stages using single-axis (Thal/Braak) and integrated A/T composite models. METHODS: We enrolled 237 AD spectrum participants undergoing …

kr, us (code pays fourni par la source)

Cerebrospinal fluid MTBR243 tau correlates with [18F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures

Philip B. Verghese, Matthew R. Meyer, Shin‐Cheng Tzeng, Christina Rabe et autres

BACKGROUND: Tau tangle neuropathology can be visualized in living individuals using radioligands that bind specifically to aggregated tau. MTBR243 is a biomarker that has been found to be strongly associated with the presence of tau tangles in the brain. In this analysis …

us, ch (code pays fourni par la source)

The Effect of Patient Age and Sex on Decision-Making Around An Alzheimer’s Disease Blood Test: QUIP II Study Results

Mark Monane, Kim G. Johnson, Daniel Parker, Robert G. Carlile et autres

Abstract Blood biomarker (BBM) tests for Alzheimer’s disease represent accurate and accessible tools to aid healthcare providers (HCPs) in the evaluation of patients presenting with signs or symptoms of mild cognitive impairment or dementia. The objective of this analysis was to examine …

us (code pays fourni par la source)

Differential Performance of p ‐tau217 in Reflecting Amyloid and Tau Stages in Cognitively Unimpaired and Impaired Individuals

Han‐Kyeol Kim, Jae Hoon Lee, Joong‐Hyun Chun, Mina Park et autres

Abstract Background This study aimed to assess the differential predictive performance of plasma p ‐tau217 for early and advanced stages of amyloid and tau pathology in cognitively unimpaired (CU) and cognitively impaired (CI) individuals, evaluating its stage‐specific utility across cognitive states. Methods …

kr, us (code pays fourni par la source)

APOE Genotype Modulates the Relationship Between Plasma p ‐tau217 and Amyloid Burden in Alzheimer's Disease

Han‐Kyeol Kim, Jae Hoon Lee, Joong‐Hyun Chun, Mina Park et autres

BACKGROUND: This study aimed to investigate the differential association between plasma p-tau217 and amyloid burden across Apolipoprotein E (APOE) genotypes. METHODS: F-flortaucipir (FTP) PET, and plasma biomarker assessments, including %p-tau217, p-tau217, and APS2. Participants were categorized based on their APOE genotype: E2+ …

kr, us (code pays fourni par la source)

APOE genotype-dependent association between plasma p-tau217 and amyloid pathology in Alzheimer’s disease

Han-Kyeol Kim, Jae Hoon Lee, Joong‐Hyun Chun, Mina Park et autres

kr, us (code pays fourni par la source)

Plasma biomarkers for predicting pet-based stages of amyloid and tau pathology in Alzheimer's disease

Han-Kyeol Kim, J. H. Lee, Joong‐Hyun Chun, Mina Park et autres

kr, us (code pays fourni par la source)

Plasma biomarkers correspond with ATN neuroimaging markers in Alzheimer's disease

Hanna Cho, Han-Kyeol Kim, Jae Hoon Lee, Joong‐Hyun Chun et autres

kr, us (code pays fourni par la source)

Performance of plasma p-tau217 in distinguishing amyloid and tau pathology differs by cognitive impairment status

Hanna Cho, Han-Kyeol Kim, J. H. Lee, Joong‐Hyun Chun et autres

kr, us (code pays fourni par la source)

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig et autres

Abstract Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small molecule, binds to an iron-responsive element in APP mRNA and decreases …

us (code pays fourni par la source)